After 26 weeks , mean HbA1c was 7.1 % ( 54 mmol/mol ) for both groups , with IDegAsp achieving the prespecified noninferiority margin for mean change in HbA1c ( estimated treatment difference [ ETD ] -0.03 % points [ 95 % CI -0.18 to 0.13 ] ) .